U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Mon Mar 31 22:37:02 GMT 2025
Edited
by admin
on Mon Mar 31 22:37:02 GMT 2025
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
805SU96HKF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTOCHROME P450 3A5
Common Name English
CYP3A5
Preferred Name English
CYTOCHROME P450-PCN3
Common Name English
CYTOCHROME P 450 3A5
Common Name English
CYTOCHROME P450 HLP2
Common Name English
HUMAN CYTOCHROME P450 3A5
Common Name English
Code System Code Type Description
UNIPROT
P20815
Created by admin on Mon Mar 31 22:37:03 GMT 2025 , Edited by admin on Mon Mar 31 22:37:03 GMT 2025
PRIMARY
FDA UNII
805SU96HKF
Created by admin on Mon Mar 31 22:37:03 GMT 2025 , Edited by admin on Mon Mar 31 22:37:03 GMT 2025
PRIMARY
CAS
336874-97-6
Created by admin on Mon Mar 31 22:37:03 GMT 2025 , Edited by admin on Mon Mar 31 22:37:03 GMT 2025
PRIMARY
Related Record Type Details
Structure of CHENODIOL
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of ELAGOLIX
INHIBITOR -> TARGET
Ki
Structure of Oxcarbazepine
INDUCER -> METABOLIC ENZYME
CHROMATOGRAPHIC PURITY (HPLC/UV)
Ki
Structure of OSILODROSTAT
INHIBITOR -> METABOLIC ENZYME
WEAK INHIBITION
Structure of LASOFOXIFENE
SUBSTRATE -> METABOLIC ENZYME
Structure of PIMECROLIMUS
SUBSTRATE -> METABOLIC ENZYME
Structure of Nifedipine
SUBSTRATE -> METABOLIC ENZYME
Structure of LORLATINIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of RIFAMPIN
INDUCER -> METABOLIC ENZYME
Structure of LUSUTROMBOPAG
INHIBITOR -> TARGET
Structure of LEMBOREXANT
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of OTENABANT
SUBSTRATE -> METABOLIC ENZYME
TROGLITAZONE
INDUCER -> METABOLIC ENZYME
Structure of Carbamazepine
INDUCER -> METABOLIC ENZYME
Structure of CARFILZOMIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of PRASTERONE
SUBSTRATE -> METABOLIC ENZYME
Structure of ALVESPIMYCIN
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of PONESIMOD
SUBSTRATE -> METABOLIC ENZYME
Structure of QUINIDINE
SUBSTRATE -> METABOLIC ENZYME
Structure of FLUOXETINE
SUBSTRATE -> METABOLIC ENZYME
Structure of Hydrocortisone
SUBSTRATE -> METABOLIC ENZYME
Structure of TEMSIROLIMUS
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of Diazepam
SUBSTRATE -> METABOLIC ENZYME
Structure of EPIANDROSTERONE
SUBSTRATE -> METABOLIC ENZYME
Structure of Irinotecan
SUBSTRATE -> METABOLIC ENZYME
Structure of Axitinib
SUBSTRATE -> METABOLIC ENZYME
Structure of TEZACAFTOR
SUBSTRATE -> METABOLIC ENZYME
Structure of Atazanavir
SUBSTRATE -> METABOLIC ENZYME
Structure of ABT-384
SUBSTRATE -> METABOLIC ENZYME
Structure of 20(S)-GINSENOSIDE RH2
SUBSTRATE -> METABOLIC ENZYME
Structure of ALLITINIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of EXEMESTANE
SUBSTRATE -> METABOLIC ENZYME
Structure of PARATHION
SUBSTRATE -> METABOLIC ENZYME
Structure of RIFAPENTINE
INDUCER -> METABOLIC ENZYME
Structure of TROLEANDOMYCIN
INDUCER -> METABOLIC ENZYME
Structure of DIETHYLTOLUAMIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of NORENDOXIFEN
INHIBITOR -> METABOLIC ENZYME
Structure of Pralsetinib
INHIBITOR -> METABOLIC ENZYME
TIME-DEPENDENT INHIBITION
Structure of ELEXACAFTOR
SUBSTRATE -> METABOLIC ENZYME
Structure of RIVOCERANIB
SUBSTRATE -> METABOLIC ENZYME
Structure of SELUMETINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of CJ-13610
SUBSTRATE -> METABOLIC ENZYME
Structure of EBASTINE
SUBSTRATE -> METABOLIC ENZYME
Structure of ALFENTANIL
SUBSTRATE -> METABOLIC ENZYME
Structure of ENZALUTAMIDE
INHIBITOR -> METABOLIC ENZYME
Structure of RIVOGLITAZONE
SUBSTRATE -> METABOLIC ENZYME
Structure of LOVASTATIN
SUBSTRATE -> METABOLIC ENZYME
Structure of TERFENADINE
SUBSTRATE -> METABOLIC ENZYME
Structure of TRIAZOLAM
SUBSTRATE -> METABOLIC ENZYME
Structure of VERAPAMIL
SUBSTRATE -> METABOLIC ENZYME
Structure of E-NORENDOXIFEN
INHIBITOR -> METABOLIC ENZYME
Structure of CABAZITAXEL
SUBSTRATE -> METABOLIC ENZYME
As cabazitaxel is mainly metabolized by CYP3A in vitro, strong CYP3A inducers or inhibitors are expected to affect the pharmacokinetics of cabazitaxel.
MAJOR
Structure of VERINURAD
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of EVATANEPAG
SUBSTRATE -> METABOLIC ENZYME
Structure of ARTEMETHER
SUBSTRATE -> METABOLIC ENZYME
Structure of EZLOPITANT
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of MIDAZOLAM
SUBSTRATE -> METABOLIC ENZYME
Structure of BMS-823778 FREE BASE
SUBSTRATE -> METABOLIC ENZYME
Structure of PARITAPREVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of ESAXERENONE
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of ELETRIPTAN
SUBSTRATE -> METABOLIC ENZYME
Structure of DOCETAXEL ANHYDROUS
SUBSTRATE -> METABOLIC ENZYME
Structure of IXABEPILONE
SUBSTRATE -> METABOLIC ENZYME
Structure of Acetaminophen
SUBSTRATE -> METABOLIC ENZYME
Structure of PHENYTOIN
INDUCER -> METABOLIC ENZYME
Structure of METHOXYCHLOR
SUBSTRATE -> METABOLIC ENZYME
Structure of Perampanel
SUBSTRATE -> METABOLIC ENZYME
Structure of Teriflunomide
NON-SUBSTRATE -> METABOLIC ENZYME
Structure of DEXAMETHASONE
INDUCER -> METABOLIC ENZYME
Structure of Venetoclax
SUBSTRATE -> METABOLIC ENZYME
Structure of Isavuconazole
SUBSTRATE -> METABOLIC ENZYME
Structure of Carbamazepine
SUBSTRATE -> METABOLIC ENZYME
Structure of SULFINPYRAZONE
INDUCER -> METABOLIC ENZYME
Structure of Isavuconazole
INDUCER -> METABOLIC ENZYME
Structure of ARTEMOTIL
SUBSTRATE -> METABOLIC ENZYME
Structure of VOXELOTOR
SUBSTRATE -> METABOLIC ENZYME
In vitro metabolism studies involving recombinant enzymes indicated that CYP3A4, CYP1A1, CYP3A5, CYP2C9, CYP2C19 and CYP2B6 were responsible for the oxidative metabolism of voxelotor.
HUMAN LIVER
TISSUE EXPRESSION -> PARENT
Structure of PIMAVANSERIN
SUBSTRATE -> METABOLIC ENZYME
Structure of TESTOSTERONE
SUBSTRATE -> METABOLIC ENZYME
Structure of LONAFARNIB
SUBSTRATE -> METABOLIC ENZYME
Structure of RIFABUTIN
INDUCER -> METABOLIC ENZYME
Structure of CYCLOPHOSPHAMIDE ANHYDROUS
SUBSTRATE -> METABOLIC ENZYME
Structure of GLECAPREVIR
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of VARDENAFIL
SUBSTRATE -> METABOLIC ENZYME
Structure of Vismodegib
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of AZD-7268
SUBSTRATE -> METABOLIC ENZYME
MAJOR
HUMAN TYPE I COLLAGEN (LUNG)
TISSUE EXPRESSION -> PARENT
Structure of SELEGILINE
SUBSTRATE -> METABOLIC ENZYME
Structure of SAQUINAVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of PEXACERFONT
SUBSTRATE -> METABOLIC ENZYME
Structure of SEMAGACESTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of CLINDAMYCIN
SUBSTRATE -> METABOLIC ENZYME
Structure of Pralsetinib
INDUCER -> METABOLIC ENZYME
Structure of Abemaciclib
SUBSTRATE -> METABOLIC ENZYME
Structure of FELODIPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of CERALASERTIB
SUBSTRATE -> METABOLIC ENZYME
Structure of AMPRENAVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of ARGATROBAN ANHYDROUS
SUBSTRATE -> METABOLIC ENZYME
Structure of IVACAFTOR
SUBSTRATE -> METABOLIC ENZYME
Structure of Erythromycin
SUBSTRATE -> METABOLIC ENZYME
Structure of Cyclosporine
SUBSTRATE -> METABOLIC ENZYME
Structure of RETAPAMULIN
SUBSTRATE -> METABOLIC ENZYME
Structure of PF-05212377
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of BENIDIPINE
SUBSTRATE -> METABOLIC ENZYME
Structure of NALOXEGOL
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of BUSPIRONE
SUBSTRATE -> METABOLIC ENZYME
Structure of PACLITAXEL
INDUCER -> METABOLIC ENZYME
Structure of VINCRISTINE
SUBSTRATE -> METABOLIC ENZYME
CYP3A5 was more efficient in catalyzing the formation of M1 compared with CYP3A4 (9- to 14-fold higher intrinsic clearance for CYP3A5).
Structure of Digitoxin
SUBSTRATE -> METABOLIC ENZYME
Structure of LIQUIRITIGENIN
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of IROSUSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of Dextromethorphan
SUBSTRATE -> METABOLIC ENZYME
Structure of Buprenorphine
SUBSTRATE -> METABOLIC ENZYME
Structure of SIMVASTATIN
SUBSTRATE -> METABOLIC ENZYME
Structure of SILDENAFIL
SUBSTRATE -> METABOLIC ENZYME
Structure of OSIMERTINIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of SAXAGLIPTIN ANHYDROUS
SUBSTRATE -> METABOLIC ENZYME
Related Record Type Details
Structure of TENAPANOR
PARENT -> IMPURITY
Tenapanor is a substrate of CYP3A4 and CYP3A5; however, none of the CYP enzymes was found to be responsible for ?25% of its overall elimination.

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO_ACID_SUBSTITUTION [1_441] CYSTEINE Amount: HEME CYSTEINE COMPLEX XW1PA2GTW0
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966